fluoromount gtm mounting medium southern biotech (SouthernBiotech)
SouthernBiotech is a verified supplier 
96
Structured Review
SouthernBiotech
fluoromount gtm mounting medium southern biotech
Fluoromount Gtm Mounting Medium Southern Biotech, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 96/100, based on 4703 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluoromount+gtm+mounting+medium+southern+biotech/DAPI+Fluoromount-G/pm39420094-274-5-8
Average 96 stars, based on 4703 article reviews
Fluoromount Gtm Mounting Medium Southern Biotech, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 96/100, based on 4703 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluoromount+gtm+mounting+medium+southern+biotech/DAPI+Fluoromount-G/pm39420094-274-5-8
Average 96 stars, based on 4703 article reviews
fluoromount gtm mounting medium southern biotech - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
Microscopy:Article Title: An Orai1 gain-of-function tubular aggregate myopathy mouse model phenocopies key features of the human disease. Article Snippet: Tubular aggregate myopathy (TAM) is a heritable myopathy primarily characterized by progressive muscle weakness, elevated levels of creatine kinase (CK), hypocalcemia, exercise intolerance, and the presence of tubular aggregates (TAs).. Here, we generated a knock-in mouse model based on a human gain-of-function mutation which results in a severe, early-onset form of TAM, by inducing a glycine-to-serine point mutation in the ORAI1 pore (Orai1 or GS mice).. By 8 months of age, GS mice exhibited significant muscle weakness, exercise intolerance, elevated CK levels, hypocalcemia, and robust TA presence. Membrane:Article Title: An Orai1 gain-of-function tubular aggregate myopathy mouse model phenocopies key features of the human disease. Article Snippet: Tubular aggregate myopathy (TAM) is a heritable myopathy primarily characterized by progressive muscle weakness, elevated levels of creatine kinase (CK), hypocalcemia, exercise intolerance, and the presence of tubular aggregates (TAs).. Here, we generated a knock-in mouse model based on a human gain-of-function mutation which results in a severe, early-onset form of TAM, by inducing a glycine-to-serine point mutation in the ORAI1 pore (Orai1 or GS mice).. By 8 months of age, GS mice exhibited significant muscle weakness, exercise intolerance, elevated CK levels, hypocalcemia, and robust TA presence. Bicinchoninic Acid Protein Assay:Article Title: An Orai1 gain-of-function tubular aggregate myopathy mouse model phenocopies key features of the human disease. Article Snippet: Tubular aggregate myopathy (TAM) is a heritable myopathy primarily characterized by progressive muscle weakness, elevated levels of creatine kinase (CK), hypocalcemia, exercise intolerance, and the presence of tubular aggregates (TAs).. Here, we generated a knock-in mouse model based on a human gain-of-function mutation which results in a severe, early-onset form of TAM, by inducing a glycine-to-serine point mutation in the ORAI1 pore (Orai1 or GS mice).. By 8 months of age, GS mice exhibited significant muscle weakness, exercise intolerance, elevated CK levels, hypocalcemia, and robust TA presence. Kinase Assay:Article Title: An Orai1 gain-of-function tubular aggregate myopathy mouse model phenocopies key features of the human disease. Article Snippet: Tubular aggregate myopathy (TAM) is a heritable myopathy primarily characterized by progressive muscle weakness, elevated levels of creatine kinase (CK), hypocalcemia, exercise intolerance, and the presence of tubular aggregates (TAs).. Here, we generated a knock-in mouse model based on a human gain-of-function mutation which results in a severe, early-onset form of TAM, by inducing a glycine-to-serine point mutation in the ORAI1 pore (Orai1 or GS mice).. By 8 months of age, GS mice exhibited significant muscle weakness, exercise intolerance, elevated CK levels, hypocalcemia, and robust TA presence. Activity Assay:Article Title: An Orai1 gain-of-function tubular aggregate myopathy mouse model phenocopies key features of the human disease. Article Snippet: Tubular aggregate myopathy (TAM) is a heritable myopathy primarily characterized by progressive muscle weakness, elevated levels of creatine kinase (CK), hypocalcemia, exercise intolerance, and the presence of tubular aggregates (TAs).. Here, we generated a knock-in mouse model based on a human gain-of-function mutation which results in a severe, early-onset form of TAM, by inducing a glycine-to-serine point mutation in the ORAI1 pore (Orai1 or GS mice).. By 8 months of age, GS mice exhibited significant muscle weakness, exercise intolerance, elevated CK levels, hypocalcemia, and robust TA presence. Software:Article Title: An Orai1 gain-of-function tubular aggregate myopathy mouse model phenocopies key features of the human disease. Article Snippet: Tubular aggregate myopathy (TAM) is a heritable myopathy primarily characterized by progressive muscle weakness, elevated levels of creatine kinase (CK), hypocalcemia, exercise intolerance, and the presence of tubular aggregates (TAs).. Here, we generated a knock-in mouse model based on a human gain-of-function mutation which results in a severe, early-onset form of TAM, by inducing a glycine-to-serine point mutation in the ORAI1 pore (Orai1 or GS mice).. By 8 months of age, GS mice exhibited significant muscle weakness, exercise intolerance, elevated CK levels, hypocalcemia, and robust TA presence. Data-independent acquisition:Article Title: An Orai1 gain-of-function tubular aggregate myopathy mouse model phenocopies key features of the human disease. Article Snippet: Tubular aggregate myopathy (TAM) is a heritable myopathy primarily characterized by progressive muscle weakness, elevated levels of creatine kinase (CK), hypocalcemia, exercise intolerance, and the presence of tubular aggregates (TAs).. Here, we generated a knock-in mouse model based on a human gain-of-function mutation which results in a severe, early-onset form of TAM, by inducing a glycine-to-serine point mutation in the ORAI1 pore (Orai1 or GS mice).. By 8 months of age, GS mice exhibited significant muscle weakness, exercise intolerance, elevated CK levels, hypocalcemia, and robust TA presence. |